Quick Takeaways
- URGN - UroGen Pharma Ltd. has 16 insiders with reported activity on this page.
- Net insider value flow over the last year: -$1,382,715.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 16 Insiders of UroGen Pharma Ltd.
- Symbol
- URGN on Nasdaq
- Location
- Ra'anana, Israel
What Changed
- Buy value: ; sell value: $1,382,715.
- Net share flow: -67,279.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$1,382,715.
Buys
$0
Shares: 0
Insiders: 0
Sells
$1,382,715
Shares: 67,279
Insiders: 3
Net
-$1,382,715
Shares: -67,279
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 10,000 | $0 | $300,000 | -$300,000 |
| 3-6 | 0 | 24,852 | $0 | $542,436 | -$542,436 |
| 6-9 | 0 | 4,594 | $0 | $82,813 | -$82,813 |
| 9-12 | 0 | 27,833 | $0 | $457,467 | -$457,467 |
UroGen Pharma Ltd. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ran Nussbaum | Director | $26,747,876 | Mixed | 21 Oct 2022 | ||
| Mark Schoenberg | Chief Medical Officer | $4,049,550 | -$1,025,315 | -20% | Filing P/S | 08 May 2026 |
| Jason Drew Smith | General Counsel | $1,094,527 | -$320,280 | -23% | Filing P/S | 31 Jan 2026 |
| Dong Kim | Chief Financial Officer | $493,809 | Mixed | 09 Sep 2024 | ||
| Molly Henderson | Chief Financial Officer | $94,516 | Mixed | 31 Jan 2022 | ||
| James A. Robinson Jr. | Director | $84,320 | Mixed | 26 Feb 2026 | ||
| Leana Wen | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Stuart Holden | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Daniel George Wildman | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Cynthia M. Butitta | Director | $39,560 | Mixed | 26 Nov 2025 | ||
| Chris Degnan | Chief Financial Officer | $38,418 | -$37,121 | -49% | Filing P/S | 31 Jan 2026 |
| Arie Belldegrun | Director | Mixed | 26 Aug 2025 | |||
| Elizabeth A. Barrett | Chief Executive Officer | Mixed | 31 Jan 2026 | |||
| Kathryn E. Falberg | Director | Mixed | 07 Jun 2021 | |||
| Shawn Tomasello | Director | Mixed | 07 Jun 2021 | |||
| Fred E. Cohen | Director | Mixed | 06 Aug 2024 |
Top shareholders of UroGen Pharma Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
13F
|
Company |
9.3%
|
4,543,895
|
$81,699,232 | — | 31 Mar 2026 | |
| TORONTO DOMINION BANK |
13D/G
13F
|
The Toronto-Dominion Bank · Company |
5.4%
|
2,616,714
|
$53,066,960 | +$6,375,626 | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.2%
from 13D/G
|
2,845,567
|
$51,163,295 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
2,560,038
|
$46,029,492 | — | 31 Mar 2026 | |
| Kynam Capital Management, LP |
13F
|
Company |
4.6%
|
2,247,393
|
$40,408,126 | — | 31 Mar 2026 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
4.5%
|
2,199,652
|
$39,549,743 | — | 31 Mar 2026 | |
| Paradigm Biocapital Advisors LP |
13D/G
13F
|
Company |
3.5%
|
1,703,949
|
$34,556,086 | -$50,946,098 | 31 Mar 2026 | |
| Soleus Capital Master Fund, L.P. |
13D/G
|
— |
4.7%
|
2,185,000
|
$31,114,400 | -$1,993,600 | 30 Jun 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
3.4%
|
1,673,420
|
$30,088,092 | — | 31 Mar 2026 | |
| SG Americas Securities, LLC |
13F
|
Company |
3.4%
|
1,657,846
|
$29,808,000 | — | 31 Mar 2026 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
3.4%
|
1,637,570
|
$29,443,545 | — | 31 Mar 2026 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.1%
|
1,503,045
|
$27,024,749 | — | 31 Mar 2026 | |
| Ran Nussbaum |
3/4/5
|
Director |
—
class O/S missing
|
1,485,168
|
$26,747,876 | — | 21 Oct 2022 | |
| Opaleye Management Inc. |
13F
|
Company |
2.9%
|
1,430,000
|
$25,711,400 | — | 31 Mar 2026 | |
| MENORA MIVTACHIM HOLDINGS LTD. |
13D/G
13F
|
Company |
5%
|
2,303,031
|
$24,780,614 | $0 | 11 Mar 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
2.7%
|
1,314,112
|
$23,627,742 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2.1%
|
1,023,159
|
$18,396,399 | — | 31 Mar 2026 | |
| MPM BioImpact LLC |
13F
|
Company |
1.9%
|
943,803
|
$16,969,578 | — | 31 Mar 2026 | |
| J. Goldman & Co LP |
13F
|
Company |
1.9%
|
938,870
|
$16,880,883 | — | 31 Mar 2026 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.8%
|
875,487
|
$15,741,256 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
1.8%
|
874,176
|
$15,717,684 | — | 31 Mar 2026 | |
| Migdal Insurance & Financial Holdings Ltd. |
13F
|
Company |
1.6%
|
770,909
|
$13,860,944 | — | 31 Mar 2026 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
2.8%
|
1,277,000
|
$13,740,520 | -$17,765,685 | 31 Mar 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.5%
|
727,000
|
$13,071,460 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
598,528
|
$10,761,534 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
523,831
|
$9,418,481 | — | 31 Mar 2026 | |
| Woodline Partners LP |
13F
|
Company |
1%
|
500,726
|
$9,003,053 | — | 31 Mar 2026 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1%
|
500,000
|
$8,990,000 | — | 31 Mar 2026 | |
| Monograph Capital Holdings Advisors, LLC |
13D/G
|
Monograph Capital Partners I, L.P. |
1.8%
|
838,615
|
$8,503,556 | $0 | 05 Jun 2025 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
0.84%
|
409,557
|
$7,363,835 | — | 31 Mar 2026 | |
| TCG Crossover Management, LLC |
13F
|
Company |
0.83%
|
405,365
|
$7,288,463 | — | 31 Mar 2026 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
0.8%
|
387,371
|
$6,964,931 | — | 31 Mar 2026 | |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND |
13F
|
Company |
0.8%
|
387,074
|
$6,959,591 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.76%
|
370,898
|
$6,668,746 | — | 31 Mar 2026 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.72%
|
350,000
|
$6,293,000 | — | 31 Mar 2026 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.59%
|
285,834
|
$5,139,295 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.57%
|
275,938
|
$4,961,365 | — | 31 Mar 2026 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.56%
|
275,000
|
$4,944,500 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.55%
|
267,996
|
$4,818,568 | — | 31 Mar 2026 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.49%
|
238,122
|
$4,281,434 | — | 31 Mar 2026 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.49%
|
236,192
|
$4,246,732 | — | 31 Mar 2026 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.47%
|
230,630
|
$4,146,727 | — | 31 Mar 2026 | |
| Mark Schoenberg |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
154,985
mixed-class rows
|
$4,049,550 | -$1,025,315 | 08 May 2026 | |
| Elmind Capital, LP |
13F
|
Company |
0.45%
|
220,000
|
$3,955,600 | — | 31 Mar 2026 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.38%
|
183,504
|
$3,299,402 | — | 31 Mar 2026 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.37%
|
177,901
|
$3,198,660 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.33%
|
159,658
|
$2,870,651 | — | 31 Mar 2026 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.32%
|
158,111
|
$2,842,834 | — | 31 Mar 2026 | |
| Atom Investors LP |
13F
|
Company |
0.3%
|
145,342
|
$2,613,249 | — | 31 Mar 2026 | |
| FMR LLC |
13F
|
Company |
0.3%
|
144,961
|
$2,606,404 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for UroGen Pharma Ltd.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -6.9% | $300,000 | $30.00 | -10,000 | 134,985 | 08 May 2026 | Direct |
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -12.7% | $147,262 | $19.69 | -7,479 | 51,326 | 03 Feb 2026 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -4.84% | $145,174 | $19.69 | -7,373 | 144,985 | 03 Feb 2026 | Direct |
| Elizabeth A. Barrett | URGN | Restricted Stock Units | Award | 153,195 | 153,195 | 31 Jan 2026 | Direct | |||
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 35.8% | 15,500 | 58,805 | 31 Jan 2026 | Direct | ||
| Jason Drew Smith | URGN | Restricted Stock Units | Award | 32,609 | 32,609 | 31 Jan 2026 | Direct | |||
| Jason Drew Smith | URGN | Restricted Stock Units | Options Exercise | -100% | -15,500 | 0 | 31 Jan 2026 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 9.59% | 13,333 | 152,358 | 31 Jan 2026 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Award | 20,000 | 20,000 | 31 Jan 2026 | Direct | |||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -100% | -13,333 | 0 | 31 Jan 2026 | Direct | ||
| Chris Degnan | URGN | Restricted Stock Units | Award | 32,609 | 32,609 | 31 Jan 2026 | Direct | |||
| Stuart Holden | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Stuart Holden | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Cynthia M. Butitta | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Cynthia M. Butitta | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| James A. Robinson Jr. | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Leana Wen | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Leana Wen | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Daniel George Wildman | URGN | ordinary shares | Options Exercise | 2,000 | 2,000 | 26 Nov 2025 | Direct | |||
| Daniel George Wildman | URGN | Restricted Stock Unit | Options Exercise | -25% | -2,000 | 6,000 | 26 Nov 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -6.71% | $250,000 | $25.00 | -10,000 | 139,025 | 19 Nov 2025 | Direct |
| Chris Degnan | URGN | Ordinary Shares | Sale | -49.1% | $37,121 | $16.85 | -2,203 | 2,280 | 08 Oct 2025 | Direct |
| Chris Degnan | URGN | Ordinary Shares | Options Exercise | 4,483 | 4,483 | 08 Oct 2025 | Direct | |||
| Chris Degnan | URGN | Restricted Stock Units | Options Exercise | -33.3% | -4,483 | 8,967 | 08 Oct 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -0.58% | $16,645 | $19.11 | -871 | 149,025 | 08 Sep 2025 | Direct |
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -3.39% | $29,047 | $19.11 | -1,520 | 43,305 | 08 Sep 2025 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 1.12% | 1,667 | 149,896 | 07 Sep 2025 | Direct | ||
| Mark Schoenberg | URGN | Restricted Stock Units | Options Exercise | -50% | -1,667 | 1,667 | 07 Sep 2025 | Direct | ||
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 8.03% | 3,333 | 44,825 | 07 Sep 2025 | Direct | ||
| Jason Drew Smith | URGN | Restricted Stock Units | Options Exercise | -50% | -3,333 | 3,334 | 07 Sep 2025 | Direct | ||
| Daniel George Wildman | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Daniel George Wildman | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| James A. Robinson Jr. | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Stuart Holden | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Stuart Holden | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Cynthia M. Butitta | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Cynthia M. Butitta | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Leana Wen | URGN | Restricted Stock Unit | Award | 8,000 | 8,000 | 26 Aug 2025 | Direct | |||
| Leana Wen | URGN | Stock Option (right ot buy) | Award | 10,000 | 10,000 | 26 Aug 2025 | Direct | |||
| Arie Belldegrun | URGN | Stock Option (right ot buy) | Award | 20,000 | 20,000 | 26 Aug 2025 | Direct | |||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -6.32% | $176,900 | $17.69 | -10,000 | 148,229 | 11 Aug 2025 | Direct |
| Elizabeth A. Barrett | URGN | Performance Stock Units | Award | 87,615 | 87,615 | 28 Jul 2025 | Direct | |||
| Jason Drew Smith | URGN | Ordinary Shares | Sale | -15.4% | $143,971 | $19.14 | -7,522 | 41,492 | 28 Jul 2025 | Direct |
| Jason Drew Smith | URGN | Ordinary Shares | Options Exercise | 50.8% | 16,500 | 49,014 | 28 Jul 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -3.15% | $98,552 | $19.14 | -5,149 | 158,229 | 28 Jul 2025 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 6.52% | 10,000 | 163,378 | 28 Jul 2025 | Direct | ||
| Mark Schoenberg | URGN | Ordinary Shares | Sale | -3.26% | $38,044 | $7.37 | -5,162 | 153,378 | 09 Jun 2025 | Direct |
| Mark Schoenberg | URGN | Ordinary Shares | Options Exercise | 6.73% | 10,000 | 158,540 | 08 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.